Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859857 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Bexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT02859857 is a Phase 1 study that has completed, run by Bexion Pharmaceuticals. The registered enrollment target is 86 participants.
The verdict
NCT02859857, a Phase 1 study, has completed, sponsored by Bexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
The objective of this study is to characterize the safety profile and determine the maximum tolerate dose (MTD) of BXQ-350, when given as a single agent at escalating doses, according to the investigational product (IP) related dose-limiting toxicities (DLTs) in patients with advanced solid tumors. Secondarily to assess the preliminary antitumor activity of BXQ-350 in solid tumors and recurrent high grade gliomas.
Interventions
- DRUG BXQ-350
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2020-06-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02859857
The ClinicalTrials.gov registry entry for NCT02859857 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bexion Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BXQ-350 is the first listed.
NCT02859857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02859857 about?
NCT02859857 is a clinical study titled "Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors". The objective of this study is to characterize the safety profile and determine the maximum tolerate dose (MTD) of BXQ-350, when given as a single agent at escalating doses, according to the investigational product (IP) related dose-limiting toxicities (DLTs) in patients with advanced solid tumors. ...
What is the current status of trial NCT02859857?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2016-09-01. Estimated completion is 2020-06-15.
What interventions are being tested in trial NCT02859857?
The interventions under investigation include: BXQ-350 (DRUG).
Who is sponsoring clinical trial NCT02859857?
This trial is sponsored by Bexion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.